VentriPoint DiagnosticsVPTDF -4.66%8 14-Day RSI is 40.26 as of Jul. 04, 2026. GuruFocus rates VPTDF with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 870 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks better than 86.44% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
VentriPoint Diagnostics 14-Day RSI Related Terms
VPTDF vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, VentriPoint Diagnostics's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a 14-Day RSI of 40.26 as of Jul. 04, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #118 out of 870 companies in the Medical Devices & Instruments industry, placing it in the top 13.6%.
Is VentriPoint Diagnostics' 14-Day RSI too high?
VentriPoint Diagnostics' current 14-Day RSI is 40.26. The Medical Devices & Instruments industry median 14-Day RSI is 47.56. VentriPoint Diagnostics' value of 40.26 is 15.3% below this industry median. Based on the distribution chart, VentriPoint Diagnostics ranks #118 out of 870 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, VentriPoint Diagnostics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #118 out of 870 companies for 14-Day RSI. This places VentriPoint Diagnostics in the top 14% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 47.56. VentriPoint Diagnostics' value of 40.26 is 15.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 47.56, based on 870 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VentriPoint Diagnostics's current 14-Day RSI of 40.26 is 15.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 47.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current 14-Day RSI is 40.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current 14-Day RSI of 40.26. The current 14-Day RSI is 40.26 and 15.3% below the Medical Devices & Instruments industry median of 47.56. VentriPoint Diagnostics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current 14-Day RSI is 40.26 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
8GF Score
Get the complete analysis for VPTDF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 